# A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

> **NCT06620003** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Albert B. Sabin Vaccine Institute** · enrollment: 200 (estimated)

## Conditions studied

- Marburg Virus Disease

## Interventions

- **BIOLOGICAL:** cAd3-Marburg Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06620003
- **Lead sponsor:** Albert B. Sabin Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-14
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620003, "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06620003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*